NewGenIvf Group Limited (NIVF) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 11, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the F-1/A for FY2025, filed Sep 1, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the NIVF SEC filings page.
NewGenIvf Group Limited (NIVF) reported $4.7M in revenue for fiscal year 2025, down 13.0% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Operating weakness shifted into reported profit while cash outflow and financing-led balance-sheet expansion continued.
In FY2025, reported net income of$9.9M coexisted with operating cash flow of-$10.9M , showing that the accounting profit did not convert into cash from operations. That gap makes earnings quality the central interpretive issue: the bottom line and the underlying cash engine moved in opposite directions.
The business’s margin structure weakened sharply: gross margin fell from
The balance sheet expanded dramatically, with assets reaching
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of NewGenIvf Group Limited's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
NewGenIvf Group Limited's reported operating margin for fiscal year 2025 is below the lowest share of revenue this page publishes, so the figure is not shown here. This dimension scores 8/100.
NewGenIvf Group Limited's revenue declined 13.0% year-over-year, from $5.4M to $4.7M. This contraction results in a growth score of 19/100.
NewGenIvf Group Limited carries a low D/E ratio of 0.25, meaning only $0.25 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 72/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 3.12, NewGenIvf Group Limited holds $3.12 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 80/100.
NewGenIvf Group Limited's reported free cash flow margin for fiscal year 2025 is below the lowest share of revenue this page publishes, so the figure is not shown here. This dimension scores 2/100.
NewGenIvf Group Limited generates a 37.1% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 5/100.
NewGenIvf Group Limited scores -0.17, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($2.3M) relative to total liabilities ($6.7M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
NewGenIvf Group Limited passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, NewGenIvf Group Limited used $1.11 of operating cash (-$10.9M OCF vs $9.9M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely.
NewGenIvf Group Limited reported an operating loss of $10.7M against $616K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
None of these metrics is reported for Q4 2025.
Cash & Balance Sheet
NewGenIvf Group Limited held $759K in cash as of Q4 2025; long-term debt is not reported for that period.
Not reported for Q4 2025.
Not reported for Q4 2025.
Margins & Returns
None of these metrics is reported for Q4 2025.
Capital Allocation
None of these metrics is reported for Q4 2025.
NIVF Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, Interest Expense, Income Tax, Net Income, EPS (Basic), EPS (Diluted), Diluted Shares (Avg).
NIVF Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'25F-1/A | Q4'24F-1/A | Q4'2310-K | Q4'2210-K |
|---|---|---|---|---|
| Total Assets | $32.7M+814.6% | $3.6M-20.3% | $4.5M+54.5% | $2.9M |
| Current Assets | $7.4M+132.7% | $3.2M+29.0% | $2.5M+2.5% | $2.4M |
| Cash & Equivalents | $759K+65.7% | $458K+746.0% | $54K+96.3% | $28K |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Inventory | $335K+315.0% | $81K-36.0% | $126K+169.2% | $47K |
| Accounts Receivable | $167K+238.2% | $49K+425.3% | $9K-27.9% | $13K |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Total Liabilities | $6.7M+33.1% | $5.1M+307.6% | $1.2M-55.7% | $2.8M |
| Current Liabilities | $2.4M-13.0% | $2.7M+142.4% | $1.1M-56.1% | $2.6M |
| Non-Current Liabilities | $4.4M+86.8% | $2.3M+1866.0% | $119K-52.1% | $249K |
| Total Equity | $26.6M+2639.7% | -$1.0M-128.1% | $3.7M+563.4% | $563K |
| Retained Earnings | $8.9M+1002.0% | -$986K-113.7% | -$461K+22.0% | -$592K |
Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.
NIVF Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Operating Cash Flow, Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.
NIVF Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Return on Assets, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| NewGenIvf Group Limited NIVF | FY2025 | $4.7M | $9.9M | N/A | $2.3M | 31/100 |
| Modivcare Inc MODV | FY2024 | $2.8B | -$201.3M | -7.2% | $6.2M | 20/100 |
| Concord Medical CCM | FY2025 | $65.9M | -$13.3M | -20.2% | $17.9M | 29/100 |
| Amer Shared Hosp AMS | FY2025 | $28.1M | -$1.6M | -5.5% | $9.9M | 37/100 |
| Cryo-Cell Intl Inc CCEL | FY2025 | $31.6M | -$2.4M | -7.7% | $33.1M | 27/100 |
| Basel Medical Group Ltd BMGL | FY2025 | $8.9M | -$8.4M | -94.0% | $7.5M | 17/100 |
Where NewGenIvf Group Limited Ranks
Frequently Asked Questions
What is NewGenIvf Group Limited's annual revenue?
NewGenIvf Group Limited (NIVF) reported $4.7M in total revenue for fiscal year 2025. This represents a -13.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is NewGenIvf Group Limited's revenue growing?
NewGenIvf Group Limited (NIVF) revenue declined by 13.0% year-over-year, from $5.4M to $4.7M in fiscal year 2025.
Is NewGenIvf Group Limited profitable?
Yes, NewGenIvf Group Limited (NIVF) reported a net income of $9.9M in fiscal year 2025.
What is NewGenIvf Group Limited's EBITDA?
NewGenIvf Group Limited (NIVF) had EBITDA of -$10.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is NewGenIvf Group Limited's gross margin?
NewGenIvf Group Limited (NIVF) had a gross margin of 20.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is NewGenIvf Group Limited's return on equity (ROE)?
NewGenIvf Group Limited (NIVF) has a return on equity of 37.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is NewGenIvf Group Limited's free cash flow?
NewGenIvf Group Limited (NIVF) recorded an outflow of $11.1M in free cash flow during fiscal year 2025. This represents a -33.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is NewGenIvf Group Limited's operating cash flow?
NewGenIvf Group Limited (NIVF) recorded an outflow of $10.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are NewGenIvf Group Limited's total assets?
NewGenIvf Group Limited (NIVF) had $32.7M in total assets as of fiscal year 2025, including both current and long-term assets.
What are NewGenIvf Group Limited's capital expenditures?
NewGenIvf Group Limited (NIVF) invested $135K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is NewGenIvf Group Limited's current ratio?
NewGenIvf Group Limited (NIVF) had a current ratio of 3.12 as of fiscal year 2025, which is generally considered healthy.
What is NewGenIvf Group Limited's debt-to-equity ratio?
NewGenIvf Group Limited (NIVF) had a debt-to-equity ratio of 0.25 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is NewGenIvf Group Limited's return on assets (ROA)?
NewGenIvf Group Limited (NIVF) had a return on assets of 30.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is NewGenIvf Group Limited's P/E ratio?
NewGenIvf Group Limited (NIVF) trades at 0.2x earnings, its market capitalization divided by net income of $9.9M net income, FY2025. The market capitalization is $2.3M as of Sep 11, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is NewGenIvf Group Limited's price-to-sales ratio?
NewGenIvf Group Limited (NIVF) trades at 0.5x sales, its market capitalization divided by revenue of $4.7M revenue, FY2025. The market capitalization is $2.3M as of Sep 11, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does NewGenIvf Group Limited's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, NewGenIvf Group Limited (NIVF) held $759K in cash, cash equivalents and investments, and reported an operating cash outflow of $10.9M over that year. Dividing the one by the other, the reported balance equals about 1 month of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is NewGenIvf Group Limited's Altman Z-Score?
NewGenIvf Group Limited (NIVF) has an Altman Z-Score of -0.17, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is NewGenIvf Group Limited's Piotroski F-Score?
NewGenIvf Group Limited (NIVF) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are NewGenIvf Group Limited's earnings high quality?
For every $1 of reported earnings, NewGenIvf Group Limited (NIVF) used $1.11 of operating cash (-$10.9M OCF vs $9.9M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can NewGenIvf Group Limited cover its interest payments?
NewGenIvf Group Limited (NIVF) reported an operating loss of $10.7M against $616K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is NewGenIvf Group Limited?
NewGenIvf Group Limited (NIVF) scores 31 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.